Sign inJoin waitlistJoin the waitlist

Matthew Reilley

Director - Phase 1 Trial Program, Director - GI Medical Oncology Research · University of Virginia Medical Center

Credentials: · · · · · ·

History

Phase 1 Trial Program, - GI Medical Oncology Research · University of Virginia Medical Center
Present
University of Virginia Medical Center
Present

Internal Medicine
University of Virginia Medical Center
2023–2026
Hematology and Medical Oncology
University of Texas Health Science Center at Houston
2014–2017
University of Pennsylvania
2011–2014
Warren Alpert Medical School of Brown University
2007–2011

Research

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
Journal for ImmunoTherapy of Cancer · 2018 · First of 27 authors · 221 citations
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Cancer Immunology Research · 2017 · 150 citations
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway
Clinical Cancer Research · 2018 · 89 citations

Tri Le
6 papers
David Hong
5 papers
Lee Ritterband
4 papers
Todd Bauer
4 papers
Bryan Schneider
3 papers
Kenneth Nepple
3 papers
Paul Kunk
3 papers
Sarina Piha-Paul
3 papers
Stephen Edge
3 papers
Apostolia Tsimberidou
2 papers
Aung Naing
2 papers
AM
Autumn McRee
2 papers

Clinical trials

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma
Principal investigator · Not yet recruiting · Phase 1, Phase 2
University of Virginia
2026–2030
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030